Literature DB >> 31728854

The TP53 p.R337H mutation is uncommon in a Brazilian cohort of pediatric patients diagnosed with ependymoma.

Taciani de Almeida Magalhães1, Kleiton Silva Borges2, Graziella Ribeiro de Sousa1, Silvia Regina Brandalise3,4, Ana Luiza Seidinger3,4, Carlos Alberto Scrideli5, Sueli Mieko Oba-Shinjo6, José Andrés Yunes3,4, Luiz Gonzaga Tone1,5.   

Abstract

BACKGROUND: Ependymoma (EPN) is the third most common childhood cancer of the central nervous system. RELA fusion-positive EPN accounts for approximately 70% of all childhood supratentorial tumors and shows the worst prognosis among the supratentorial EPNs. TP53 mutation is infrequent in RELA fusions EPNs. In the population from the Southern region of Brazil, there is a high incidence of the germline TP53 p.R337H mutation that predisposes carriers to develop early-onset tumors. However, despite this high incidence, the frequency of this mutation among EPN patients remains to be determined. Here, we investigated the presence of the TP53 p.R337H mutation in a larger cohort of pediatric EPNs of three institutions located in the state of São Paulo, Brazil.
METHODS: The TP53 p.R337H mutation was screened by conventional RT-PCR and Sanger sequencing in 49 pediatric EPNs diagnosed during the period from 1995 to 2016.
RESULTS: We described for the first time a case of a 5-year-old girl with RELA fusion EPN with a heterozygous TP53 p.R337H mutation.
CONCLUSIONS: The present finding indicates that the TP53 p.R337H germline mutation is uncommon in patients with EPN in Brazil and screening of pediatric patients RELA fusion EPN may be informative to better understand the role of TP53 germline mutations in the development and prognosis of these tumors.

Entities:  

Keywords:  Pediatric ependymoma; RELA fusion; Southern Brazil; TP53 p.R337H mutation

Year:  2019        PMID: 31728854     DOI: 10.1007/s10072-019-04112-x

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  25 in total

1.  Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome.

Authors:  J M Limacher; T Frebourg; S Natarajan-Ame; J P Bergerat
Journal:  Int J Cancer       Date:  2001-08-20       Impact factor: 7.396

2.  Identification of a germ-line mutation in the p53 gene in a patient with an intracranial ependymoma.

Authors:  A K Metzger; V C Sheffield; G Duyk; L Daneshvar; M S Edwards; P H Cogen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

3.  Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in southeast Brazil.

Authors:  Ana Luiza Seidinger; Maria José Mastellaro; Fernanda Paschoal Fortes; Juliana Godoy Assumpção; Izilda Aparecida Cardinalli; Mônica Aparecida Ganazza; Raul Correa Ribeiro; Silvia Regina Brandalise; Simone Dos Santos Aguiar; José Andrés Yunes
Journal:  Cancer       Date:  2010-12-29       Impact factor: 6.860

4.  DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment.

Authors:  Hendrik Witt; Dorothee Gramatzki; Bettina Hentschel; Kristian W Pajtler; Jörg Felsberg; Gabriele Schackert; Markus Löffler; David Capper; Felix Sahm; Martin Sill; Andreas von Deimling; Marcel Kool; Ulrich Herrlinger; Manfred Westphal; Torsten Pietsch; Guido Reifenberger; Stefan M Pfister; Jörg C Tonn; Michael Weller
Journal:  Neuro Oncol       Date:  2018-11-12       Impact factor: 12.300

Review 5.  Rare occurrence of inactivating p53 gene mutations in primary non-astrocytic tumors of the central nervous system: reappraisal by yeast functional assay.

Authors:  M Nozaki; M Tada; R Matsumoto; Y Sawamura; H Abe; R D Iggo
Journal:  Acta Neuropathol       Date:  1998-03       Impact factor: 17.088

6.  Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification.

Authors:  J Imamura; C R Bartram; F Berthold; D Harms; H Nakamura; H P Koeffler
Journal:  Cancer Res       Date:  1993-09-01       Impact factor: 12.701

7.  Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors.

Authors:  Gislaine Custódio; Guilherme A Parise; Nilton Kiesel Filho; Heloisa Komechen; Cesar C Sabbaga; Roberto Rosati; Leila Grisa; Ivy Z S Parise; Mara A D Pianovski; Carmem M C M Fiori; Jorge A Ledesma; José Renato S Barbosa; Francisco R O Figueiredo; Elis R Sade; Humberto Ibañez; Sohaila B I Arram; Sérvio T Stinghen; Luciano R Mengarelli; Mirna M O Figueiredo; Danilo C Carvalho; Sylvio G A Avilla; Thiago D Woiski; Lisiane C Poncio; Geneci F R Lima; Roberto Pontarolo; Enzo Lalli; Yinmei Zhou; Gerard P Zambetti; Raul C Ribeiro; Bonald C Figueiredo
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

8.  Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.

Authors:  Nataliya Zhukova; Vijay Ramaswamy; Marc Remke; Elke Pfaff; David J H Shih; Dianna C Martin; Pedro Castelo-Branco; Berivan Baskin; Peter N Ray; Eric Bouffet; André O von Bueren; David T W Jones; Paul A Northcott; Marcel Kool; Dominik Sturm; Trevor J Pugh; Scott L Pomeroy; Yoon-Jae Cho; Torsten Pietsch; Marco Gessi; Stefan Rutkowski; Laszlo Bognar; Almos Klekner; Byung-Kyu Cho; Seung-Ki Kim; Kyu-Chang Wang; Charles G Eberhart; Michelle Fevre-Montange; Maryam Fouladi; Pim J French; Max Kros; Wieslawa A Grajkowska; Nalin Gupta; William A Weiss; Peter Hauser; Nada Jabado; Anne Jouvet; Shin Jung; Toshihiro Kumabe; Boleslaw Lach; Jeffrey R Leonard; Joshua B Rubin; Linda M Liau; Luca Massimi; Ian F Pollack; Young Shin Ra; Erwin G Van Meir; Karel Zitterbart; Ulrich Schüller; Rebecca M Hill; Janet C Lindsey; Ed C Schwalbe; Simon Bailey; David W Ellison; Cynthia Hawkins; David Malkin; Steven C Clifford; Andrey Korshunov; Stefan Pfister; Michael D Taylor; Uri Tabori
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

9.  Association of the germline TP53 R337H mutation with breast cancer in southern Brazil.

Authors:  Juliana G Assumpção; Ana Luíza Seidinger; Maria José Mastellaro; Raul C Ribeiro; Gerard P Zambetti; Ramapriya Ganti; Kumar Srivastava; Sheila Shurtleff; Deqing Pei; Luiz Carlos Zeferino; Rozany M Dufloth; Silvia Regina Brandalise; José Andres Yunes
Journal:  BMC Cancer       Date:  2008-12-01       Impact factor: 4.430

10.  C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma.

Authors:  Matthew Parker; Kumarasamypet M Mohankumar; Chandanamali Punchihewa; Ricardo Weinlich; James D Dalton; Yongjin Li; Ryan Lee; Ruth G Tatevossian; Timothy N Phoenix; Radhika Thiruvenkatam; Elsie White; Bo Tang; Wilda Orisme; Kirti Gupta; Michael Rusch; Xiang Chen; Yuxin Li; Panduka Nagahawhatte; Erin Hedlund; David Finkelstein; Gang Wu; Sheila Shurtleff; John Easton; Kristy Boggs; Donald Yergeau; Bhavin Vadodaria; Heather L Mulder; Jared Becksfort; Jared Becksford; Pankaj Gupta; Robert Huether; Jing Ma; Guangchun Song; Amar Gajjar; Thomas Merchant; Frederick Boop; Amy A Smith; Li Ding; Charles Lu; Kerri Ochoa; David Zhao; Robert S Fulton; Lucinda L Fulton; Elaine R Mardis; Richard K Wilson; James R Downing; Douglas R Green; Jinghui Zhang; David W Ellison; Richard J Gilbertson
Journal:  Nature       Date:  2014-02-19       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.